News
Sorrento and Mount Sinai Team Up for Antibody Cocktail COVI-SHIELD Project
San Diego-based Sorrento Therapeutics is teaming up with New York City-based Mount Sinai Health System to develop an antibody cocktail called COVI-SHIELD to treat COVID-19.
The partnership is aimed at creating antibody products that could act as a “protective shield”...
Drug Research
Vault Health Delivers Access to the First FDA EUA Approved At-Home Saliva Test for COVID-19
For the first time, Americans will have access to at-home testing for COVID-19 through Vault Health, utilizing the first FDA EUA approved saliva test from RUCDR Infinite Biologics and Spectrum Solutions.
Vault Health, a startup specializing in healthcare for men,...
News
Recipharm secures supply of drug substance and commences manufacture of chloroquine phosphate
Recipharm, a leading contract development and manufacturing organisation (CDMO), has now secured supply of the active pharmaceutical ingredient (API) chloroquine phosphate for its drug Klorokinfosfat RPH Pharma and commenced manufacture of the product.
The move comes following reports that chloroquine...
Clinical Trials
Humanigen Initiates Phase III Lenzilumab Study in COVID-19
Humanigen, Inc., has dosed the first COVID-19 patient in its Phase III study for lenzilumab, its Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody. Catalent provides clinical supply support to Humanigen and its partners from its Philadelphia facility.
“We...
News
BARDA Funds Development of Tangen Biosciences Multi-Target Platform
The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has awarded Tangen the Second Option of a contract to develop a molecular diagnostic platform that can be used by Tangen Biosciences Inc. to...
News
Rescheduled CPhI South East Asia to now take place in November 2020
CPhI South East Asia – organised by Informa Markets – has postponed its rescheduled event to November 4-6, 2020 to provide more time for positive business conditions to return and for global disruption to ease.
“Moving the event to November...
News
AI-based precision medicine mining of UK Biobank finds 13 human COVID risk genes and identifies 59 drugs with potential to improve survival in severe...
Data scientists from UK-headquartered AI precision medicine company, PrecisionLife, have used the Company’s proprietary AI enabled precision medicine platform to identify 59 repurposing drug candidates that could be used to develop new therapeutic strategies to increase the survival rate...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read